Key result
Oral anticoagulant type shows no association with recurrent stroke or systemic embolism after AF-related stroke.
Why the study?
Evidence is lacking regarding the optimal therapeutic approach for patients who experience recurrent stroke while receiving anticoagulation.
Does the type of oral anticoagulant affect the risk of recurrent ischemic stroke, TIA, or systemic embolism in patients with atrial fibrillation-related stroke?
Does the type of oral anticoagulant affect the risk of recurrent ischemic stroke, TIA, or systemic embolism in patients with atrial fibrillation-related stroke?
In patients with atrial fibrillation-related stroke, the type of oral anticoagulant was not associated with recurrence, though underdosing and subtherapeutic levels were prevalent.
Answers are grounded in this paper and cite their sources.
Should not yet alter anticoagulant choice in AF-related stroke; leaves open optimal dosing and recurrence risks for prospective study.
Introduction:The cardioembolic stroke recurrence rate could be up to 10% in the first year and increase over time.Evidence is lacking concerning the best therapeutic approach in patients with recurrent stroke while on anticoagulation.Objective: To explore the relationship between the type of anticoagulant and the composite outcome of ischemic stroke, transient ischemic attack (TIA) or systemic embolism in anticoagulated patients with a recurrent atrial fibrillation-related stroke. Materials and method:A cross-sectional study involving patients who were treated in the stroke unit from 2014-2019 for atrial fibrillation-related stroke.Patients with clinical records after the index stroke were considered.They were classified as recurrent/non-recurrent and were compared in terms of sociodemographic factors, comorbidities and the oral anticoagulant used.The recurrent group was characterized according to severity, dosing and plasma anticoagulation levels.Results: 60 patients were included (17 with recurrence and 43 without recurrence); in the patients with recurrence, 82.3% of the events were strokes, 17.6% were TIAs, and there were no systemic emboli, with a median recurrence time of 398 days.No relationship was found between the type of anticoagulation and the pre-specified outcomes, although a considerable prevalence of underdosing and subtherapeutic blood anticoagulant levels was found.Conclusion: No relationship can be established between the type of anticoagulant and recurrence.Possible explanatory factors were identified; however, the study of these factors and their role in the occurrence of the event is beyond the aim and scope of the present study and should be elucidated in future studies.
No takes yet. Share an insight, caveat, or question.
Sánchez-Acosta et al. (2023) studied this question. The type of oral anticoagulant was not associated with recurrent ischemic stroke, TIA, or systemic embolism in 60 patients with a prior atrial fibrillation-related stroke.
Synapse has enriched 10 related papers. Consider them for comparative context: